SCHEMBL29353981

SCHEMBL29353981

FC(F)(F)c1nc2ccccc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 1.00
ALDH1A1 P00352 8/20 0.58
KDM4E B2RXH2 8/20 0.58
MAPT P10636 5/20 0.58
GAA P10253 4/20 0.58
PKM P14618 3/20 0.58
KHK P50053 1/20 0.58
HPGD P15428 4/20 0.56
HSD17B10 Q99714 3/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
ALOX15 P16050 1/20 0.56
CYP2C19 P33261 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.54
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
ABCB11 O95342 1/20 0.54
TP53 P04637 1/20 0.54
POLB P06746 4/20 0.53
MEN1 O00255 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10295 1.00 NPSR1 (1.00) NPSR1ALDH1A1KDM4EMAPTGAA
Pyrrolidine SCHEMBL4724716 0.88 NPSR1 (0.77) NPSR1ALDH1A1KDM4EMAPTGAA
Diphenylether SCHEMBL4184182 0.88 NPSR1 (0.77) NPSR1ALDH1A1KDM4EMAPTGAA
SCHEMBL4374246 0.88 NPSR1 (0.78) NPSR1ALDH1A1KDM4EMAPTGAA
SCHEMBL9960528 0.86 NPSR1 (0.75) NPSR1ALDH1A1KDM4EMAPTGAA
SCHEMBL23854433 0.84 NPSR1 (0.72) NPSR1ALDH1A1KDM4EMAPTGAA
SCHEMBL5015526 0.84 NPSR1 (0.72) NPSR1ALDH1A1KDM4EMAPTGAA
SCHEMBL7532421 0.84 NPSR1 (0.72) NPSR1ALDH1A1KDM4EMAPTGAA
SCHEMBL13049405 0.84 NPSR1 (0.72) NPSR1ALDH1A1KDM4EMAPTGAA
SCHEMBL7532738 0.84 NPSR1 (0.72) NPSR1ALDH1A1KDM4EMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117285985-A Low-dynamic surface tension insulating layer buffer cleaning liquid and preparation method and application thereof 四川格林达电子材料有限公司 2023-12-26 CN claimed
CN-112581856-B Temperature indicating label 苏州和萃新材料有限公司 2022-07-19 CN claimed
US-20250346922-A1 COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION TENAYA THERAPEUTICS INC (US) 2025-11-13 US disclosed
EP-3910715-B1 ADHESIVE ELECTROLYTE TESA SE (DE) 2025-07-09 EP disclosed
CN-116194439-B SOCE inhibitors and therapeutic uses thereof 国家医疗保健研究所 2025-04-08 CN disclosed
CN-118063453-B Benzimidazole derivative, preparation method and application thereof, and agricultural bactericide 南京吉星生物技术开发有限公司 2025-02-07 CN disclosed
US-12201617-B2 HDAC6 inhibitors for treatment of metabolic disease and HFpEF TENAYA THERAPEUTICS, INC. (US) 2025-01-21 US disclosed
EP-4486807-A1 PRESSURE-SENSITIVE ADHESIVE COMPOSITION TESA SE (DE) 2025-01-08 EP disclosed
US-20240269137-A1 HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY TENAYA THERAPEUTICS, INC. 2024-08-15 US disclosed
US-20240252502-A1 HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF TENAYA THERAPEUTICS, INC. 2024-08-01 US disclosed
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 US disclosed
EP-4157822-A1 SOCE INHIBITORS AND THERAPEUTIC USES THEREOF Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2023-04-05 EP disclosed
CN-111377907-B Polysubstituted phenylamino pyrimidine derivative and preparation method and application thereof 杭州百新生物医药科技有限公司 2023-03-28 CN disclosed
CN-112581856-B Temperature indicating label 苏州和萃新材料有限公司 2022-07-19 CN disclosed
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-06-09 US disclosed
CN-114230523-A Benzimidazole derivatives as modulators of ROR-gamma 生命医药有限责任公司 2022-03-25 CN disclosed
CN-114149418-A High morpholine compound, preparation method, pharmaceutical composition and application 天津医科大学 2022-03-08 CN disclosed
US-20220064150-A1 SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS PTC THERAPEUTICS INC (US) 2022-03-03 US disclosed
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2022-02-08 US disclosed
US-11230554-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2022-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240269137-A1 HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY HDAC6, HDAC1, HDAC2 NPSR1 4240/4885ALDH1A1 452/4885KDM4E 1451/4885
US-11230554-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds SSB, TPMT, ADAR NPSR1 1818/4885ALDH1A1 2152/4885KDM4E 1602/4885
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 NPSR1 58/4885ALDH1A1 761/4885KDM4E 2755/4885
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 NPSR1 58/4885ALDH1A1 761/4885KDM4E 2755/4885
US-20240252502-A1 HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF HDAC6, HDAC1, HDAC2 NPSR1 2594/4885ALDH1A1 176/4885KDM4E 1342/4885
US-12201617-B2 HDAC6 inhibitors for treatment of metabolic disease and HFpEF HDAC6, HDAC1, HDAC2 NPSR1 2594/4885ALDH1A1 176/4885KDM4E 1342/4885
US-20220064150-A1 SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS BMI1, BRPF3, BAZ2A NPSR1 4854/4885ALDH1A1 1803/4885KDM4E 155/4885
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 NPSR1 58/4885ALDH1A1 761/4885KDM4E 2755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.